anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There are over 750,000 individuals in the U.S. with Cerebral Palsy (CP). Up to 46% of adults with CP report limited mobility in their communities. However, upper limb spasticity and motor control impairment can make the independent use of a wheelchair difficult. Forty percent of individuals who desire mobility via electric wheelchairs are precluded from using them because of problems with upper limb function including motor, sensory, or cognitive impairments that can make the use of a conventional joystick difficult. No studies to date have produced devices that definitively improve mobility for these individuals. We will recruit 22 subjects with Spastic CP and 22 age and gender matched control subjects without apparent disability from advertisements, mailings, and outpatient clinics. Both a conventional motion sensing joystick (MSJ) and a novel isometric joystick that is customized for each subject will each be used to maneuver a sprite on a computer screen in six different tasks. Each task involves a path with 90-degree turns. Two tasks have paths that are completely visible to the subject, while four have paths that appear either immediately or at 1, 2, or 3 seconds ahead of the sprite. Because subjects with CP and control subjects are likely to drive at different speeds, subjects will drive under conditions of freely chosen speed and with speed controlled at 1.2 m/s. Joystick input signals that represent the sprite's velocity and position will be recorded. Changes in direction and speed, average deviation from path center, number of boundary violations, start and stop reaction times, response times to turns, and duration of subject movement will be calculated. We will use a Repeated Measures design, treating speed as a covariate under the condition when it is freely chosen. We hypothesize that, regardless of joystick or speed condition, subjects with Spastic CP will have more direction and speed changes, greater average deviation from path center, more boundary violations, prolonged reaction times and response times to turns, and prolonged subject movement time compared to controls. We hypothesize that, regardless of joystick or speed condition, decreasing warning time before turns will be correlated with more direction and speed changes, greater average deviation from path center, more boundary violations, and prolonged subject movement time and that the magnitude of these changes will be greater for those with Spastic CP. We hypothesize that, regardless of speed condition, subjects with Spastic CP, when using a MSJ compared to the isometric joystick, will have more direction and speed changes, greater average path deviation, more boundary violations, and prolonged subject movement. Understanding driving task deficits and warning time for movement decisions will help to identify customization parameters for joysticks and other assistive devices, not only for CP but for Traumatic Brain Injury, Spinal Cord Injury, Parkinson's Disease, stroke, or a variety of other disabilities.
In this arm, patients are distributed free dental hygiene samples, and given advice on reading the customised website. This arm is compared to Arm 1.
Biocompatible, triggerable degradation, polymerizable hydrogels, uses and delivery devices are disclosed. These hydrogels are at least substantially water soluble macromers, having a variety of uses especially for ocular therapy. The macromers include at least one water soluble region, at least one region which is degradable via a triggering event, usually by hydrolysis, and at least two free radical-polymerizable regions. The regions can, in some embodiments, be both water soluble and trigger able degradable. The macromers are polymerized by exposure of the polymerizable regions to free radicals generated by photosensitive chemicals and dyes. An advantage of these polymer hydrogels is that they can be polymerized rapidly in an aqueous surrounding. Precisely conforming, semi-permeable, biodegradable films or membranes can thus be formed on tissue in situ to serve as biodegradable barriers, as carriers for living cells or other biologically active materials, and as surgical adhesives for the eye.
Calcium Fructoborate (CFB), is a proprietary, safe generally-recognized-as-safe (GRAS) supplement. The only content of the supplement is CFB - there are no excipients, binders, or flow agents, nor are there any other materials. 216mg of CFB will be administered daily for 90 days.
The invention relates to a houttuynia cordata fermentation liquid with relieving, repairing, anti-inflammatory and antibacterial effects, and a preparation method and application thereof, and belongs to the technical field of microbial fermentation. The invention discloses Monascus purpureus (Monascus anka) MF02, and the preservation number of the Monascus purpureus in China center for type culture collection is CCTCC No. M2023750. The invention also discloses a cordate houttuynia fermentation liquor with the effects of relieving, repairing, anti-inflammatory and antibacterial, which is prepared by fermenting monascus purpureus, wherein the preservation number of the monascus purpureus is CCTCC No. M2023750. The invention utilizes liquid fermentation of plant endophytic fungi and medicinal plants, and biologically converts cordate houttuynia raw materials in a mild way through the activities and metabolism of microorganisms, so that the obtained fermentation liquor has high active substance content and good effects of relieving, repairing, resisting inflammation and resisting bacteria.
Child health and survival remain significant challenges in Nepal. Nepal is ranks 63rd highest in the world for "under 5 mortality" rate, with 54/1000 children dying before their 5th birthdays and 46/1000 infants dying before their first birthdays. Annually, more than 47,000 children die before reaching age 5 years. At these mortality levels, one in every 22 Nepalese children dies before reaching age 1, and one in every 19 does not survive to his or her fifth birthday. Nutritional status of children is extremely poor, with \~29% of children underweight and 41% stunted (respectively, weight and height \<-2 SD from median) (UNICEF, 2011) (Ministry of Health and Population et al., 2012).

Heifer Project International is a globally active NGO with more than 400 projects in over 30 countries. The organization uses the introduction of livestock and related training in the development of social capital as tools for poverty alleviation, citizen empowerment, and community development. Heifer International recognizes the links between poverty, child malnutrition, and disease. However, improving economic indicators is not always sufficient to improve child outcomes. Thus, the organization now wishes to conduct a systematic assessment to evaluate the effects of introducing a child health and nutrition component into their work, and to clarify the links (if any) between social capital training and child growth and health. In doing so, Heifer International expects to develop a model which could be adapted for use in other regions of the world. The interaction of Heifer community development activities, specific child and family characteristics, and child health and nutritional status will also be explored.
The patient will be given a laser diode brace to wear for 1 year. At the defined time points following surgery (2, 4, 6, 8, 12, 24, 36 and 48 weeks), subjects will be asked to complete pain and ability-to-function questionnaires and submit scar/wound images to determine their status at each time interval.
The management of patients with peripheral arterial disease (PAD) stage IIb and pain-free walking distance (PFWD) less than 100 meters is a major clinical problem, in view of the significant cooling of the quality of life and evolution often severe that characterizes the clinical course of these patients. Revascularization Surgery is the treatment of choice, but about half of patients with severe PAD IIb is not eligible for surgery or endovascular treatment. The usefulness of use of vasodilators or hemorheological is controversial, and medical treatment of these patients is therefore heterogeneous understanding the various pharmacologic options (for the correction of risk factors, prevention of cardiovascular events, improvement of claudication), and rehabilitative programs. Iloprost, a synthetic analogue of prostacyclin, is effective in the treatment of patients with chronic critical ischemia, and its pharmacological profile (effective vasodilator, anti-platelet, and leukocyte activation) is particularly suitable to modulate multiple components pathogenesis of peripheral arterial disease. Specifically, in the treatment of patients with PAD IIb severe, the current state is available only a retrospective study that compared the use of iloprost with that of vasodilators. Aim of the study FADOI-2bPILOT is to evaluate prospectively and for an observation period of 13 months, if you can get a benefit on the pain-free walking distance and on clinical outcome from "anticipated" and additional use of iloprost, in patients with severe IIb stage PAD treated according to current "best medical practice".
Study participants randomized to the Health Education intervention will attend 14 sessions with a Health Educator over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
PROBLEM TO BE SOLVED: To obtain a plaster capable of improving the obstruction properties by including a metallic oxide therein. SOLUTION: This plaster is obtained by including a metallic oxide such as titanium dioxide, red iron oxide, yellow iron oxide or black iron oxide, providing a matrix for the plaster, then coating a support with the resultant matrix and fixing the matrix thereon. The metallic oxide prepared by carrying out the pulverizing treatment with a pulverizer or a bantam mixer is preferably used without causing aggregation. Since the matrix contains the metallic oxide as an obstruction enhancer, excellent obstruction effects are manifested when attaching the matrix to the support and using thereof as the plaster. Thereby, the percutaneous absorptivity of the pharmacodynamically effective agent is improved.  Since contact dermatitis, etc., are hardly manifested, excellent actions on the percutaneous administration of an agent whose percutaneous administration is difficult or an agent requiring the controlled release are manifested.
1,143,502. Moulding artificial teeth. WILLIAMS GOLD REFINING CO. Inc. 15 Feb., 1966, No. 6508/66. Heading B5A. [Also in Divisions A5 and C3] Artificial teeth and veneers and inlays therefor are moulded from a synthetic resin prepared by polymerizing a mixture of a solid, finely divided, methyl methacrylate polymer and a polymerizable liquid dimethacrylate or diacrylate ester, said ester being the sole liquid component of the mixture and being derived from a C 3-8  polyhydric aliphatic alcohol, or a polyethylene glycol or polypropylene glycol each having a degree of polymerization from 2 to 6, and being less volatile than dibutyl phthalate. The resin, which may contain pigments, may be moulded wholly or partly about a core of solid polymethyl methacrylate to form an artificial tooth. Amongst the pigments which may be used are titanium dioxide, the oxides of copper, zinc, iron and cobalt, and mixtures thereof. Fillers including chopped glass fibres may be used.
Analgesic compositions administered by rubbing into the skin comprise at least one analgesic and at least one dialkyl sulphoxide. Exemplified analgesics comprise aspirin, phenacetin, paracetamol and phenylbutazone.  The dialkyl sulphoxide may be dimethyl, diethyl, di-n-propyl, methyl ethyl or methyl ethyl sulphoxide.  The compositions may be in the form of solutions, dispersions, emulsions, or pastes, and may contain conventional excipients.  One or more compounds having a local beneficial action in the treatment of painful conditions, e.g. rheumatism, may be added.  These compounds may comprise a C1-6 alkyl ester of nicotinic acid, e.g. ethyl nocotinate, and/or a C1-6 alkyl ester of salicylic acid, e.g. methyl salicylate.
Older patients face increasing challenges in preserving mobility during hospitalization. This retrospective cohort study aimed to evaluate the effect of an Occupational Therapy (OT) program on mobility at discharge in older patients admitted to an Acute Geriatric Unit (AGU). All patients aged ≥65 years consecutively admitted to the AGU in an 18-month period were included in the study if scoring <4 or ≥ 8 at the Clinical Frailty Scale. Overall, 807 patients (median age 85 years, 50.2% females) were included: 665 (82%) received OT, while 142 who did not receive OT were used as controls. The Cumulated Ambulation Scale (CAS) was used to assess mobility at discharge. By multivariable logistic regression, OT was independently associated with higher odds of achieving higher CAS score at discharge. These findings emphasize the potential benefits of OT in acute geriatric settings, providing valuable insights for preserving mobility of frail older individuals during hospitalization.
Participants will receive sorafenib, oral tablets, 400 milligrams (mg) twice daily in accordance with the package insert. Treatment is to continue until the participant is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. Medically appropriate dose adjustments and drug holidays due to adverse events (AEs) and toxicity will be allowed.
A few cases of acute overdosage with aminocaproic acid administered intravenously have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. One patient with a history of brain tumor and seizures experienced seizures after receiving an 8 gram bolus injection of aminocaproic acid. The single dose of aminocaproic acid causing symptoms of overdosage or considered to be life-threatening is unknown. Patients have tolerated doses as high as 100 grams while acute renal failure has been reported following a dose of 12 grams.

The intravenous and oral LD50 of aminocaproic acid were 3 and 12 g/kg, respectively, in the mouse and 3.2 and 16.4 g/kg, respectively, in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog. On intravenous administration, tonic-clonic convulsions were observed in dogs and mice.

No treatment for overdosage is known, although evidence exists that aminocaproic acid is removed by hemodialysis and may be removed by peritoneal dialysis. Pharmacokinetic studies have shown that total body clearance of aminocaproic acid is markedly decreased in patients with severe renal failure.
Provided are a method for treating cancer or tumor by using modified bacteria as well as a therapeutic or prophylactic composition comprising the modified bacteria. The method may combine with other treatments such as chemotherapy, radiation therapy, gene therapy, surgery or a combination thereof. The method makes modified facultative anaerobic bacteria into a conditional obligate anaerobe. Further provided are the modified bacteria comprising an essential gene expressing cassette that is strictly hypoxia regulated as well as the vector comprising the same. The modified bacteria grow within the solid tumor/cancer, rendering the retardation or elimination of the tumor/cancer from normal tissues. Also provided is the use of the modified bacteria in manufacturing a medicament for treating cancer.
In the case of placenta previa-accreta when the placenta covers the entire anterior uterine wall, it is difficult to avoid transecting the placenta by traditional low-transverse cesarean section (CS), resulting in catastrophic hemorrhage and fetal anemia. To prevent this critical risk, we developed the CS with transverse uterine fundal incision (TUFI) and this technique has been widely used as a beneficial surgical method in clinical practice owing to its safety advantages for the mother and neonate since our first report. However, the risk of uterine rupture during a subsequent pregnancy remains unclear. Based on our 17 years of experience, patients who require TUFI do not need to avoid this beneficial operative method simply because of their desire to conceive again, as long as certain conditions can be met. To approve a post-TUFI pregnancy, an appropriate suture method, delay in conception for at least 12 months with evaluation of the TUFI scar, and cautious postoperative management are at a minimum essential. In this article, we showed our recommendation for operative procedure and discuss the current status of the management of post-TUFI pregnancies based on the evaluation of the TUFI wound scar and experience with postoperative pregnancies.
PURPOSE: To compare short-term complications and readmission rates, in patients treated with simultaneous versus staged bilateral total hip arthroplasty (THA) within a year from the index procedure.
METHODS: We reviewed the charts of patients that underwent simultaneous and staged-within a year-bilateral THA, between 2016 and 2020. Preoperative baseline characteristics were evaluated, while differences in terms of 30-day major and 30-day minor complications and readmission rates were compared between the groups.
RESULTS: One-hundred-sixty patients (mean age, 64.3 years; SD, ± 11.7) were identified. Seventy-nine patients were treated with simultaneous (Group A) and eighty-one patients with staged (Group B) THA. There were no differences in baseline characteristic between the two groups (p  > 0.050). Group A was more likely to receive general anesthesia (43% vs. 9.9%, p < 0.001) and had longer total operative time (182.8 vs. 128.0 min, p  < 0.001). Group A had an overall shorter total length of hospital stay (5.8 vs. 8.6 days, p  < 0.001). No differences in transfusion rates (p  = 0.229) and no differences in major and minor complications (p > 0.05) were identified. Postoperative visits at the emergency department or readmissions were similar between the two groups (p > 0.050).
CONCLUSION: This study shows that similar complication and readmission rates are expected after simultaneous and staged THA. Simultaneous bilateral THA is a safe and effective procedure, that should be considered for patients that present with radiologic and clinical bilateral hip disease.
Atherosclerotic arterial disease is the main cause of premature death worldwide and is anticipated to remain the single leading cause of morbidity and mortality the following two decades. Coronary heart disease (CHD) and peripheral arterial disease (PAD) are important clinical manifestation of atherosclerosis which have common underlying arterial pathology, risk factors, and preventive treatments, but they are not often studied concurrently. In the view of secondary prevention we need to know more about the prevalence of cardiovascular disease and prognosis in patients at documented high risk, i.e. patients with manifested CHD. Previous studies on patients with CHD and concomitant PAD have focused mainly on either lower extremity PAD or carotid artery disease. In this project we expand the concept of PAD in patients with CHD to include lower extremity arterial disease, carotid artery disease, renal artery disease, and abdominal aortic aneurysmal disease.

Diabetes mellitus is a well recognised risk factor for cardiovascular morbidity and mortality. However, even prediabetic conditions carry an increased risk. One possible explanation for this increased risk may be the presence of a greater number of atherosclerotic lesions in patients with glucometabolic disorders than in patients without such disorders. We aim to evaluate the association of PAD with glucometabolic status in patients with manifest CHD.

A growing body of research has demonstrated the role of psychosocial and behavioural risk factors in the pathogenesis and prognosis of cardiovascular disorders. Recently, the type D ("distressed") personality construct has been proposed as a strong risk factor for cardiovascular morbidity and mortality. Type D personality is characterized by high levels of two personality traits: negative affectivity (e.g. worry, irritability, and gloom) and social inhibition (e.g. lack of self-assurance and reticence). The data on type D personality as a risk factor for cardiovascular disease has been limited to few research groups and there is a need to replicate those data in other populations.
Systems and methods for monitoring, diagnosing, and/or treating a patient are provided. One or more individual medical procedures may be utilized to monitor, diagnose and/or treat the patient. Two or more of the individual medical procedures or may be used in combination to provide more comprehensive patient monitoring, diagnosis and/or therapy. One or more functions of two or more individual medical procedures may be used in combination to enhance patient monitoring, diagnosis and/or therapy. The medical procedures may be coordinated. Coordinated medical procedures may involve cooperative operation of two or more of the individual processes. Coordinated medical procedures may also involve cooperative operation of one or more functions of two or more of the individual processes.
The present invention discloses a drop-before-add optical routing and switching system. The drop-before-add optical routing and switching system includes an input waveguide for carrying a multiplexed optical signal comprising optical signals transmitted over a plurality of wavelength channels represented by λ 1 , λ 2 , λ 3 , . . . , λ N−1  and λ N , where N is a positive integer wherein the input waveguide extending over a first direction. The drop-before-add optical routing and switching system further includes a plurality of second direction waveguides extending over a second direction and intersecting at N intersections with the input waveguide. The drop-before-add optical routing and switching system further includes a plurality of wavelength selective grating switches each disposed on one of the N intersections for selectively transmitting an optical signal of a selected wavelength into an associated one of the second direction waveguide.
The present disclosure relates to a system (100) for generating a diagnostic model. The system (100) includes a processor (108) configured to analyse a plurality of reference data sets. The reference data sets each include at least one image (230, 240). The analysis identities at least one feature in each image (230, 240). A metric is calculated in dependence on the at least one identified feature. Outcome data associated with at least some of the reference data sets is acquired. The diagnostic model is compiled in dependence on the at least one calculated metric and the associated outcome data. The present disclosure also relates to a method of generating a diagnostic model; and a non-transitory computer-readable medium.
Patients receive oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
A set of first modality data sets is received that includes at least one view that includes a plurality of gates. A first modality data set is received from a first imaging modality of an imaging system. A second modality data set is received from a second imaging modality of the imaging system. A motion corrected model of the first modality data set is generated by forward projecting the first modality data set including the motion estimation. An update factor for each of the plurality of views is generated by comparing at least one of the plurality of gates to the motion corrected model. The motion corrected model is updated by an update factor to generate a motion corrected image.